Ads
related to: icer hemophilia cost of treatment list of doctors
Search results
Results from the WOW.Com Content Network
The Institute for Clinical and Economic Review (ICER) is a Boston-based independent nonprofit organization that seeks to place a value on medical care by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures. [1] ICER was founded in about 2005 by physician-researcher Steven D. Pearson. [1]
As such, the ICER facilitates comparison of interventions across various disease states and treatments. In 2009, NICE set the nominal cost-per-QALY threshold at £50,000 for end-of-life care because dying patients typically benefit from any treatment for a matter of months, making the treatment's QALYs small. [3]
The cost of Factor VIII and similar clotting factors has been described as "highly expensive". [21] The cost of the clotting factors is 80% of all medical costs for people with hemophilia. [23] They are so expensive that gene therapy for haemophilia might be less expensive, especially for people with severe hemophilia. [23]
There’s a new one-time treatment for Hemophilia B patients in the market, but it comes with an obscene price tag. A hemophilia drug that just won FDA approval pegs a one-time $3.5 million vial ...
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
Haemophilia (British English), or hemophilia (American English) [6] (from Ancient Greek αἷμα (haîma) 'blood' and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
The incremental cost-effectiveness ratio (ICER) is the ratio between the difference in costs and the difference in benefits of two interventions. The ICER may be stated as (C1 – C0)/(E1 – E0) in a simple example where C0 and E0 represent the cost and gain, respectively, from taking no health intervention action.
Accredo Health Group, Inc. is a specialty pharmaceutical and service provider for patients with complex and chronic health conditions. [1] Accredo provides specialty drugs, drugs that cost more than $600 per month, with the average being $10,000 a month, which treat serious conditions such as multiple sclerosis, rheumatoid arthritis, hemophilia and cancer. [1]
Ads
related to: icer hemophilia cost of treatment list of doctors